CNS Pharmaceuticals Inc. Announces 1-for-12 Reverse Stock Split to Take Effect July 22

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company dedicated to developing treatments for brain and central nervous system cancers, has announced a 1-for-12 reverse stock split effective July 22, 2025. This strategic move will see every twelve shares of the company's common stock converted into one share, with corresponding adjustments made to warrants and equity awards to ensure uniformity among all shareholders. The company's stock will continue to trade under the symbol CNSP but will be assigned a new CUSIP number: 18978H508.

In lieu of issuing fractional shares, CNS Pharmaceuticals will provide cash payments to shareholders who would otherwise be entitled to receive a fraction of a share post-split. Additionally, the company has decided to reduce its authorized share count to 25 million, while maintaining the par value at $0.001 per share. This decision underscores the company's commitment to streamlining its capital structure and enhancing shareholder value.

The reverse stock split is a critical step for CNS Pharmaceuticals as it continues to focus on its clinical-stage pipeline, including its lead drug candidate, Berubicin. Berubicin represents a novel approach in the treatment of aggressive brain cancers, such as glioblastoma multiforme (GBM), by potentially crossing the blood-brain barrier, a significant challenge in CNS oncology. For more details on the reverse stock split, interested parties can view the full press release here.

This announcement is particularly significant for investors and the biopharmaceutical industry as it reflects CNS Pharmaceuticals' strategic efforts to position itself for future growth and development in the highly competitive and innovative field of CNS cancer treatments. The reverse stock split could potentially make the company's stock more attractive to institutional investors and improve its visibility in the market, thereby facilitating further research and development endeavors.